1. 106559983 具有改善的储存稳定性的药物组合物及其制备方法
CN
05.04.2017
A61K 9/107 Loading...
A61K 9/107
Loading...
201680001936.3
株式会社三养生物制药
金峰五
A61K 9/107
Loading...
本发明提供了含有规定限量以内的特定相关化合物的药物组合物及其制备方法。
2. 205994133 一种中药饮片销售架
CN
08.03.2017
A47F 7/00 Loading...
A47F 7/00
Loading...
201620606345.6
重庆灵方三帆生物制药有限公司
白涛
A47F 7/00
Loading...
本实用新型公开了一种中药饮片销售架，包括销售架本体，销售架本体包括展示架和储存箱，展示架的内部设置有纵横交错的竖挡板和两个横挡板，竖挡板和两个横挡板将展示架均匀分割成四个相同的放置腔，且两个横挡板的外表面均开设有卡槽，卡槽的内部设置有铭牌，储存箱的内部开设有四个均匀分布的存放室，且四个存放室的内部均设置有相同的存放盒，四个存放盒的一侧面上均设置有拉环，且四个存放室内部的周向均开设有第一滑槽。该中药饮片销售架，很方便将药品进行展示或者存放，不用来回的挪动，使用方便，可以保证药品的通风性良好，可以起到很好的防潮作用，保证药品的干燥，延长销售架的使用寿命，并且结构比较简单。
3. 205994132 一种乳膏剂销售架
CN
08.03.2017
A47F 7/00 Loading...
A47F 7/00
Loading...
201620605680.4
重庆灵方三帆生物制药有限公司
白涛
A47F 7/00
Loading...
本实用新型公开了一种乳膏剂销售架，包括主体，主体的顶部连接有支撑架，支撑架的内腔分别设有隔板和放置腔，放置腔的底部安装有支撑板，支撑板的顶部设有滑槽，滑槽的内腔活动连接有展示架，展示架的顶部设有置物盘，置物盘的顶部安装有分割板，展示架的内腔安装有伸缩杆，伸缩杆的顶部设有限位块。本乳膏剂销售架，结构简单，使用方便，通过伸缩杆可以方便展示架的折叠，当展示架打开时，会形成多层塔的外观，可以存放大量的乳膏剂样品，极大的节省了摆放空间，而且多层塔的设计，可以防止上层置物盘里放置的乳膏剂样品，遮挡住下层置物盘里的乳膏剂样品，方便乳膏剂样品的展示。
4. 104822668 自10‑脱乙酰巴卡丁III以高收率制造卡巴他赛的新的方法及用于该方法的新颖中间体
CN
08.03.2017
C07D 305/14 Loading...
C07D 305/14
Loading...
201380063361.4
株式会社三养生物制药
李罗荣
C07D 305/14
Loading...
本发明涉及从10‑脱乙酰巴卡丁III制造卡巴他赛的新的方法及用于该方法的新颖中间体，更详细而言涉及以10‑脱乙酰巴卡丁III作为出发物质而经新颖中间体制造卡巴他赛，可在对比以往的技术更短的时间内以高收率，高纯度更容易制造卡巴他赛而适合于产业性大量生产的方法及用于该方法的新颖中间体。
5. 205988167 一种便于取放的橡胶膏剂销售架
CN
01.03.2017
A47F 7/00 Loading...
A47F 7/00
Loading...
201620610098.7
重庆灵方三帆生物制药有限公司
白涛
A47F 7/00
Loading...
本实用新型公开了一种便于取放的橡胶膏剂销售架，包括销售架、工作箱和透明玻璃柜，所述销售架的顶部固定连接有支撑板，所述工作箱的底部固定连接在支撑板的底部，所述工作箱的正面开设有条形通槽，所述工作箱的内部开设有工作槽，所述工作槽的内部分别设置有第一转轴、齿轮和支撑转动链条，所述支撑板的顶部并位于工作箱内固定连接有固定板，固定板和工作箱的箱体内部均固定连接有轴承，齿轮套接在第一转轴的表面，所述支撑转动链条与齿轮的齿牙端啮合。本实用新型便于取放的橡胶膏剂销售架，结构简单，使用方便，对橡胶膏剂能够有顺序的摆放，并且对其起到更好的固定作用，在销售员对橡胶膏剂摆放或者拿取时更加方便。
6. 205886757 一种用于药液原料的搅拌机
CN
18.01.2017
B01F 13/10 Loading...
B01F 13/10
Loading...
202016000606342
重庆灵方三帆生物制药有限公司
白涛
B01F 13/10
Loading...
本实用新型公开了一种用于药液原料的搅拌机，包括底座，底座的顶部固定连接有搅拌机外壳，且搅拌机外壳的顶部开设有缺口，搅拌机外壳的内部设置有搅拌机内壳，且搅拌机内壳的顶部开设有注料口，搅拌机内壳的内部设置有搅拌室，搅拌机内壳的底部固定连接有密封板，密封板的内部固定连接有相对称的震动电机，密封板的底部固定连接有相对称的第一弹簧，两个第一弹簧的另一端均与底座的顶部固定连接，底座的内底壁固定连接有电机。该用于药液原料的搅拌机，有效提高搅拌效果，当搅拌机搅拌多种混合原料时，能使多种原料快速混合，使其在最短的时间内达到合格的标准，提高工作效率，降低人力的劳动量。
7. 205891615 一种中药饮片销售用的储存盒
CN
18.01.2017
B65D 51/24 Loading...
B65D 51/24
Loading...
202016000607727
重庆灵方三帆生物制药有限公司
白涛
B65D 51/24
Loading...
本实用新型公开了一种中药饮片销售用的储存盒，包括盒盖和盒体，盒盖位于盒体的顶部，所述盒盖的内部设置有分流管，该分流管的出风口与风机的吸风管连接，且分流管出风口底端的盒盖内部设置有过滤板，所述过滤板的底部设置有干燥板。该中药饮片销售用的储存盒，通过电动伸缩杆的运作，带动移动板和网板的运动，增加了中药饮片的翻动，减少了中药饮片长期接触导致中药饮片之间的连接处发霉和变质，增加了中药饮片与空气的接触，进一步增加了中药饮片在储存盒的安全和时间；整个装置，操作简单，使用方便，实用性强，有效的保护中药饮片的安全，同时，方便了销售，减少了中药饮片的浪费和成本，增加中药饮片的销售量。
8. 205886653 一种高效乳膏搅拌机
CN
18.01.2017
B01F 7/02 Loading...
B01F 7/02
Loading...
202016000610038
重庆灵方三帆生物制药有限公司
白涛
B01F 7/02
Loading...
本实用新型公开了一种高效乳膏搅拌机，包括壳体，所述壳体的底部固定连接有减震装置，所述壳体的底部且远离减震装置的一侧固定连接有支撑腿，所述壳体的内部固定连接有搅拌室，所述壳体的内壁的两侧均固定连接有电机箱，所述电机箱的内部固定连接有电机，所述电机的输出轴通过联轴器固定连接有旋转轴，所述旋转轴远离联轴器的一端贯穿搅拌室。该高效乳膏搅拌机，其设置有的菱形搅拌体，通过三百六十度旋转，全方位的对机体内的搅拌物品进行搅拌，能够快速的进行搅拌，达到搅拌均匀，提高工作效率，机体的底部设置有减震装置，在搅拌过程中减小震动，使得搅拌质量更高。
9. 205887423 一种中药饮片的原药材拣选工作台
CN
18.01.2017
B07B 1/30 Loading...
B07B 1/30
Loading...
202016000610085
重庆灵方三帆生物制药有限公司
白涛
B07B 1/30
Loading...
本实用新型公开了一种中药饮片的原药材拣选工作台，包括底台、筛选框和动力电机，所述筛选框底部的内侧设有筛选网，其筛选框左侧的外壁还设有凹槽，所述凹槽内侧的顶部与底部均安装有齿槽，所述齿槽的内侧啮合有导向齿轮，所述导向齿轮的外侧与动力电机相连接。本实用新型中药饮片的原药材拣选工作台，通过安装的滑槽、筛选框、凹槽、齿槽、导向齿轮和动力电机，使得该拣选工作台能够通过电机的带动，来进行筛选操作，有效代替了传统人工手动拨动药材的方法，使得中药饮片或中药饮片原药材的筛选速度得到有效的提高，不仅为工作人员拣选中药饮片原药材提供了方便，同时还极大的减轻了工作人员的工作量。
10. 205886744 一种乳膏剂加工用搅拌装置
CN
18.01.2017
B01F 9/22 Loading...
B01F 9/22
Loading...
202016000607615
重庆灵方三帆生物制药有限公司
白涛
B01F 9/22
Loading...
本实用新型公开了一种乳膏剂加工用搅拌装置，包括下板，所述下板的顶部通过缓冲弹簧连接有上板，所述上板的底部设置有警告按钮，所述上板的顶部从左往右依次设置有固定台和控制器，所述固定台上开设有凹槽，且凹槽中设置有电机箱。该乳膏剂加工用搅拌装置，通过电机、旋转装置、旋转桶、第一搅拌杆、第二搅拌杆和搅拌块的配合使用，使得搅拌装置可以很好对原材料进行搅拌操作，避免了由于搅拌操作不完全而导致的乳膏剂质量下降，警告按钮和控制器的配合使用，很好的控制了搅拌操作所放入的原材料质量，避免了由于原材料过多而导致的电机超负荷运作和由于原材料过少而导致的工作效率低下。
11. 205897745 一种带废热回收装置的搅拌烘干机
CN
18.01.2017
F26B 11/06 Loading...
F26B 11/06
Loading...
202016000607648
重庆灵方三帆生物制药有限公司
白涛
F26B 11/06
Loading...
本实用新型公开了一种带废热回收装置的搅拌烘干机，包括箱体，所述箱体的前表面通过铰链连接有箱门，所述箱门的一侧固定设有门拉手，所述箱门之间设置有立板，所述箱体的前表面上方分别设置有控制器和显示器，所述箱体的顶部固定设有废热回收装置，所述废热回收装置包括壳体，所述壳体内腔设有交换芯，所述交换芯的内腔设有第一管道和第二管道，所述第一管道和第二管道分别贯穿交换芯和壳体并延伸至壳体的外部。该带废热回收装置的搅拌烘干机，通过加装搅拌设备，使将要烘干的药材在滚筒内旋转、翻滚，达到了烘烤速度快和烘烤均匀的效果，通过加装废热回收装置，达到了药物烘干质量高和保护环境节约资源的效果。
12. 205886677 一种乳膏剂搅拌装置
CN
18.01.2017
B01F 7/16 Loading...
B01F 7/16
Loading...
202016000605697
重庆灵方三帆生物制药有限公司
白涛
B01F 7/16
Loading...
本实用新型公开了一种乳膏剂搅拌装置，包括底座，所述底座顶部固定连接有立柱，所述立柱的一侧固定连接有控制器，所述立柱顶部的外壁固定连接有挂环，所述立柱的中部设置有伸缩杆，所述伸缩杆远离立柱的一端固定连接有电机，所述电机上固定连接有挂钩，所述电机远离挂钩的一侧设置有转轴，所述转轴远离电机的一端贯穿药杯且延伸至药杯的内部与搅拌体固定连接，所述药杯的底部与底座活动连接。该乳膏剂搅拌装置，采用两个搅拌横杆和一个搅拌竖杆同时运转，增加了搅拌块与乳膏剂的接触面积，增大了搅拌空间，提高了搅拌效果，整个装置结构简单，操作方便，能够更大面积，更均匀的搅拌乳膏剂，提高了搅拌效率。
13. 205889282 一种用于生产橡胶膏剂的炼胶机
CN
18.01.2017
B26D 1/04 Loading...
B26D 1/04
Loading...
202016000606395
重庆灵方三帆生物制药有限公司
白涛
B26D 1/04
Loading...
本实用新型公开了一种用于生产橡胶膏剂的炼胶机，包括框架，框架的上部设置有第一支撑杆，第一支撑杆的两端均固定连接有第一连接杆，第一支撑杆一侧面的中部开设有第一滑槽，第一滑槽通过滑块固定连接有挡板，第一滑槽的外侧设置有与滑块固定连接的限位块，限位块上设置有第一调节旋钮，第一支撑杆的下侧设置有第二支撑杆，第二支撑杆上设置有炼胶轮，挡板的底部与炼胶轮固定连接，第二支撑杆的两端均固定连接有第二连接杆。该用于生产橡胶膏剂的炼胶机，方便将毛边和不完整的胶切掉，而且可以根据需要在第三支撑上增加第一刀片和第二刀片的数量，方便调节刀片的位置，且方便对胶进行切割，结构简单使用方便。
14. 205891853 一种乳化膏销售柜的自动取货传送机构
CN
18.01.2017
B65G 1/04 Loading...
B65G 1/04
Loading...
202016000605724
重庆灵方三帆生物制药有限公司
白涛
B65G 1/04
Loading...
本实用新型公开了一种乳化膏销售柜的自动取货传送机构，包括销售柜体，销售柜体的内腔设置有传送装置，传送装置的内腔设置有移动板，移动板内腔的底部套装有被动杆，被动杆的两端均套接有被动轴，被动轴的外沿与链条的内侧啮合，链条的上下两端的内侧分别啮合齿轮组和固定杆，固定杆的中部套装有传送轴，销售柜体的内腔设置有伺服电机，销售柜体的上表面从左至右依次安装有反射板、红外线装置和计数器。该乳化膏销售柜的自动取货传送机构，通过红外线装置的感应距离变化来启动和停止伺服电机，将伺服电机的启动次数通过数据传输给计数器，根据计数器显示的销售数值和存放的数值差，一次性补货到位，减轻了销售员的工作量，提高了效率。
15. 205886630 一种膏剂搅拌机
CN
18.01.2017
B01F 3/08 Loading...
B01F 3/08
Loading...
202016000605169
重庆灵方三帆生物制药有限公司
白涛
B01F 3/08
Loading...
本实用新型公开了一种膏剂搅拌机，包括底座，所述底座的前表面设置有控制面板，所述底座的右侧面固定连接有油缸，所述底座的顶部右侧设置有伸缩杆，所述伸缩杆包括第一伸缩杆和第二伸缩杆，所述第一伸缩杆与第二伸缩杆滑动连接，且第二伸缩杆位于第一伸缩杆的上方，所述第二伸缩杆的侧面设置有套管，且套管的左侧面固定连接有横梁，所述横梁的底部设置有电机安装底座。该膏剂搅拌机，结构简单，操作方便，可以加速了搅拌桶内上下不同空间位置的膏剂乳化，可以在传统机械式搅拌乳化的基础上进行超声波乳化，乳化后的介质直径更小，乳化效果高，乳化更稳定，降低了生产成本，也方便了人们对搅拌机的清洗。
16. 205887543 一种中药饮片生产用清洗设备
CN
18.01.2017
B08B 3/10 Loading...
B08B 3/10
Loading...
202016000605676
重庆灵方三帆生物制药有限公司
白涛
B08B 3/10
Loading...
本实用新型公开了一种中药饮片生产用清洗设备，包括基体和清洗箱，所述基体的顶部依次设有电机和清洗箱，所述清洗箱内腔的两侧设有发热体，清洗箱的顶部设有主干燥装置，清洗箱内腔的中部设有沥水装置。本实用新型集沥水功能和干燥功能于一体，能够使得对清洗后的原材料进行及时沥水，从而增加了该清洗设备的沥水功能，防止原材料表面积聚过多的清洗污水，大幅度提高原材料的清洗效果，且能够对沥水后的原材料进行干燥处理，迅速的除去原材料表面的污水，避免原材料受到污水的二次污染，降低了后期原材料的生产加工的难度。
17. 205889322 一种橡胶膏剂高效便捷式切割装置
CN
18.01.2017
B26D 1/25 Loading...
B26D 1/25
Loading...
202016000605159
重庆灵方三帆生物制药有限公司
白涛
B26D 1/25
Loading...
本实用新型公开了一种橡胶膏剂高效便捷式切割装置，包括外壳，外壳的两侧均开设有开口，外壳一侧的底部固定连接有第一电机，第一电机的转轴通过联轴器固定连接有第一连接杆，第一连接杆远离第一电机一端的表面固定连接有皮带轮，皮带轮通过皮带传动连接有第一旋转轴，第一旋转轴上固定连接有第一滚辊，外壳远离第一电机一侧的底部固定连接有支撑柱，支撑柱的顶端活动连接有第二旋转轴。该橡胶膏剂高效便捷式切割装置，操作简单，更好的方便了使用者的使用，避免了给使用者带来了较大的困扰，防止目前切割设备切割的效果，保证了橡胶膏剂后期正常的生产制造，缩短了工作的时间，降低了经济成本的支出和劳动力的使用。
18. 106146491 被芳基或杂芳基取代的5-羟基-1,7-萘啶化合物、其制备方法及其制药用途
CN
23.11.2016
C07D 471/04 Loading...
C07D 471/04
Loading...
102015000141555
沈阳三生制药有限责任公司
周云隆
C07D 471/04
Loading...
本发明涉及具有下式(I)的化合物或其药学上可接受的盐：其中，R1，R2各自独立为氢；R1为氢或C1‑3烷基；Ar是选自萘环、吡啶环、噻吩环、呋喃环和取代苯环的芳香环或芳杂环。本发明还涉及该化合物的制备方法，含有所述化合物或其药学上可接受的盐的药物组合物，以及所述化合物或其药学上可接受的盐在制备用于抑制HIF脯氨酸羟化酶的药物或制备促进生成内源性EPO的药物中的用途。
19. 106146395 3-羟基吡啶化合物、其制备方法及其制药用途
CN
23.11.2016
C07D 213/81 Loading...
C07D 213/81
Loading...
102015000141553
沈阳三生制药有限责任公司
周云隆
C07D 213/81
Loading...
本发明涉及具有下式(I)的化合物或其药学上可接受的盐，其中，R1，R2独立为氢；R3选自氢、C1‑C7直链、支链或环状烷基；R4，R5，R6，R7和R8各自独立地选自C1‑C7烷基、卤代C1‑C7烷基等。本发明还涉及该化合物的制备方法，含有所述化合物或其药学上可接受的盐的药物组合物，以及所述化合物或其药学上可接受的盐在制备用于抑制HIF脯氨酸羟化酶的药物或制备促进生成内源性EPO的药物中的用途。
20. 106146490 被芳氧基或杂芳氧基取代的5-羟基-1,7-萘啶化合物、其制备方法及其制药用途
CN
23.11.2016
C07D 471/04 Loading...
C07D 471/04
Loading...
102015000140858
沈阳三生制药有限责任公司
周云隆
C07D 471/04
Loading...
本发明涉及被芳氧基或杂芳氧基取代的5‑羟基‑1,7‑萘啶化合物、其制备方法及其制药用途。具体来说，本发明所述的化合物具有下式(I)，其中，R2，R3各自独立为氢；R1为氢或C1‑3烷基；Ar是选自萘环、吡啶环、噻吩环、呋喃环和取代苯环的芳香环或芳杂环。本发明还涉及该化合物的制备方法，含有所述化合物或其药学上可接受的盐的药物组合物，以及所述化合物或其药学上可接受的盐在制备用于抑制HIF脯氨酸羟化酶的药物或制备促进生成内源性EPO的药物中的用途。
21. WO/2016/155357 COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYLOXY OR HETEROOXY, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF
WO
06.10.2016
C07D 471/04 Loading...
C07D 471/04
Loading...
PCT/CN2015/097244
SHENYANG SUNSHINE PHARMACEUTICAL CO., LTD.
ZHOU, Yunlong
C07D 471/04
Loading...
The present invention relates to a compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heterooxy, a preparation method thereof and a pharmaceutical use thereof. In particular, the compound has the following formula (I), wherein R2 and R3 are each independently H; R1 is H or C1-C3alkyl; Ar is an aromatic ring or a heteroaromatic ring selected from a naphthalene ring, a pyridine ring, a thiophene ring, a furan ring and a substituted benzene ring. The present invention also relates to the method for preparing the compound, pharmaceutical compositions comprising the compound or pharmaceutically acceptable salts thereof, and uses of the compound or pharmaceutically acceptable salt thereof in the preparation of a medicine for inhibiting HIF proline hydroxylase or a medicine for promoting the generation of endogenous EPO.
22. WO/2016/155359 COMPOUND OF 3-HYDROXYL PYRIDINE, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF
WO
06.10.2016
C07D 213/81 Loading...
C07D 213/81
Loading...
PCT/CN2015/097246
SHENYANG SUNSHINE PHARMACEUTICAL CO., LTD.
ZHOU, Yunlong
C07D 213/81
Loading...
The present invention relates to a compound of the following formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are independently H; R3 is selected from H, a C1-C7straight-chain, and a branched or cyclic alkyl; and R4, R5, R6, R7, and R8 are each independently selected from C1-C7alkyl, halo C1-C7alkyl and the like. The present invention also relates to a method for preparing the compound, pharmaceutical compositions comprising the compound or pharmaceutically acceptable salts thereof, and uses of the compound or pharmaceutically acceptable salt thereof in the preparation of a medicine for inhibiting HIF proline hydroxylase or a medicine for promoting the generation of endogenous EPO.
23. WO/2016/155358 COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYL OR HETEROARYL, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF
WO
06.10.2016
C07D 471/04 Loading...
C07D 471/04
Loading...
PCT/CN2015/097245
SHENYANG SUNSHINE PHARMACEUTICAL CO., LTD.
ZHOU, Yunlong
C07D 471/04
Loading...
Disclosed are a compound of the following formula (I) or a pharmaceutically acceptable salt thereof, a preparation method thereof, pharmaceutical compositions and uses thereof in the preparation of a medicine for inhibiting HIF proline hydroxylase or a medicine for promoting the generation of endogenous EPO, wherein in the formula (I), R1 and R2 are each independently hydrogen; R3 is hydrogen or C1-3alkyl; and Ar is an aromatic ring or an heteroaromatic ring selected from a naphthalene ring, a pyridine ring, a thiophene ring, a furan ring and a substituted benzene ring.
24. 105979949 不含抗氧化剂的药物组合物及其制备方法
CN
28.09.2016
A61K 31/519 Loading...
A61K 31/519
Loading...
201480074738.0
株式会社三养生物制药
赵重雄
A61K 31/519
Loading...
公开了一种包含可容易地发生氧化降解的药物如培美曲塞且通过不使用抗氧化剂而在制备组合物的过程中除去氧而具有高稳定性的组合物；以及用于制备该组合物的方法。该制备方法通过在密闭容器中冷冻和脱气具有高度的制备便利性，并能够提供其中氧化不稳定的药物具有开创性的高稳定性的组合物。
25. 105934247 包含帕洛诺司琼的药物组合物
CN
07.09.2016
A61K 31/47 Loading...
A61K 31/47
Loading...
112014000074137
株式会社三养生物制药
尹惠靖
A61K 31/47
Loading...
本发明涉及一种包含帕洛诺司琼并具有提高的稳定性的药物组合物、该药物组合物的生产方法以及包含该药物组合物的药物包装。
26. 105832678 生物利用度提高的包含难溶性药物的微球及其制备方法
CN
10.08.2016
A61K 9/16 Loading...
A61K 9/16
Loading...
201610236147.X
株式会社三养生物制药
金京熙
A61K 9/16
Loading...
本文提供了生物利用度提高的包含难溶性药物的微球及其制备方法。所述包含难溶性药物的微球是通过喷雾干燥方法使难溶性药物以非晶体形式分散于水溶性高分子载体中的固体分散体，因此具有提高了难溶性药物的生物利用度的优点。
27. 105541994 一种血小板生成素或其变体或衍生物的纯化方法
CN
04.05.2016
C07K 14/52 Loading...
C07K 14/52
Loading...
201510869984.1
沈阳三生制药有限责任公司
娄竞
C07K 14/52
Loading...
本发明属生物制药领域，涉及一种血小板生成素或其变体或衍生物的纯化方法，其包括至少一个应用阴离子交换的柱层析步骤，具体包括下列步骤：(1)将部分纯化后或未纯化的血小板生成素或其变体或衍生物与含有季胺基或二乙氨乙基基团的阴离子交换层析填料的层析柱结合；(2)先用含有NaCl、低pH和低电导率的尿素溶液冲洗层析柱来洗脱杂蛋白；(3)再用高pH和高电导率的缓冲溶液冲洗层析柱，由此将血小板生成素从层析柱上分离下来。阴离子交换层析经含有NaCl、低pH和低电导率的尿素溶液洗脱后，杂蛋白明显减少，可有效提高中间体纯度，后续步骤综合收率提高明显。采用本发明的纯化方法纯化的血小板生成素，具有较高的纯度、活性及稳定性。
28. 105531276 用于制备高纯度培美曲塞的得到提高的中间体的制备方法及利用其来制备高纯度培美曲塞的方法
CN
27.04.2016
C07D 487/04 Loading...
C07D 487/04
Loading...
201480049311.5
株式会社三养生物制药
金荣敏
C07D 487/04
Loading...
本发明涉及一种用于制备高纯度培美曲塞的得到提高的中间体的制备方法，以及利用其来制备高纯度培美曲塞的方法，更详细地，涉及一种制备高纯度的、用于制备培美曲塞的中间体培美曲塞二乙酯或其盐的新型方法，以及使用其中间体来制备高纯度培美曲塞二钠盐的方法。
29. 105412942 聚乙二醇化的重组产朊假丝酵母尿酸氧化酶冻干注射剂
CN
23.03.2016
A61K 47/48 Loading...
A61K 47/48
Loading...
201510979806.4
沈阳三生制药有限责任公司
娄竞
A61K 47/48
Loading...
本发明提供一种治疗由人体内血尿酸升高而引起的各种疾病的聚乙二醇化重组产朊假丝酵母尿酸氧化酶冻干注射剂，其特征在于由以下成分组成：为活性成分的聚乙二醇化的重组产朊假丝酵母尿酸氧化酶、在冷冻或冻干过程种保持蛋白活性和稳定的冻干保护剂、填充剂、酸碱调节剂和维持一定pH值条件的缓冲液。其特点是保持聚乙二醇化的重组产朊假丝酵母尿酸氧化酶冻干后完整的空间构型和生物学活性，不仅有利于药物的保存，而且有利于药物在短时间内重溶并且复性。
30. 105025882 熔融挤出而成的控释药物组合物及包含其的口服制剂
CN
04.11.2015
A61K 9/16 Loading...
A61K 9/16
Loading...
201380072515.6
株式会社三养生物制药
朴庠晔
A61K 9/16
Loading...
本发明提供控释药物组合物及包含其的口服制剂，所述控释药物组合物包含熔融挤出而成的颗粒和高分子包衣层，所述熔融挤出而成的颗粒包含水不溶性甲基丙烯酸铵共聚物、聚乙酸乙烯酯和活性成分，所述高分子包衣层形成于上述颗粒表面且包含水不溶性甲基丙烯酸铵共聚物。
31. 203525835 一种胶体磨
CN
09.04.2014
B02C 23/00 Loading...
B02C 23/00
Loading...
201320604948.9
三门峡广宇生物制药有限公司
张乐营
B02C 23/00
Loading...
一种胶体磨，包括胶体磨，胶体磨上方设有冷却器，冷却器的底部设有与胶体磨上口位置对应的冷却料出口，冷却器的上料口通过输送管道与胶体磨底部连接，输送管道上分支设有下料管道，输送管道上设有上料阀门，下料管道上设有下料阀门；冷却器为水冷却器，包括冷却水套、冷却水进口和冷却水出口；冷却料出口、冷却水进口和冷却水出口处的管道上均设有阀门。本实用新型结构简单、功能实用，有效地解决了胶体磨发热问题，确保了胶体磨的连续生产，同时增加了混匀物料的量。保证了规模化生产的需求。
32. 103476431 Carrier for negatively charged drugs comprising a cationic lipid and a preparation method thereof
CN
25.12.2013
A61K 47/18 Loading...
A61K 47/18
Loading...
201180063713.7
株式会社三养生物制药
崔成源
A61K 47/18
Loading...
Disclosed are a carrier for delivering a negatively charged drug, comprising a cationic lipid represented by formula 1, and a preparation method thereof. Also disclosed is a pharmaceutical composition, comprising a negatively charged drug and a cationic lipid represented by formula 1, wherein the negatively charged drug forms a complex with the cationic lipid. The composition can increase the in vivo stability of the negatively charged drug after local or systemic administration and allows the intracellular delivery of the negatively charged drug. Thus, the composition will be useful for improving the therapeutic effect of the negatively charged drug.
33. 103432357 Preparation technology for fat soluble traditional Chinese medicine suppository
CN
11.12.2013
A61K 36/896 Loading...
A61K 36/896
Loading...
201310360593.8
三门峡广宇生物制药有限公司
王广宇
A61K 36/896
Loading...
The invention belongs to the technical field of Chinese patent medicine preparations, and particularly relates to a preparation technology for a fat soluble traditional Chinese medicine suppository. The technology comprises the following steps: smashing dragon's blood and borneol into fine powder; smashing cortex phellodendri Chinensis, common andrographis herb and radix salviae miltiorrhizae into coarse powder to be added into an extraction kettle for supercritical extraction; adding water and decocting four herbs of dandelion, bunge corydalis herb, red paeony roots and plantain; finally preparing the suppository by adding products prepared in the steps into fatty acid mixed glyceride. The fat soluble traditional Chinese medicine suppository prepared by the technology enables the medicine transdermal absorption to be more sufficient, the bioavailability is greatly improved, the medication treatment effect is greatly improved, and the cure rate of the fat soluble traditional Chinese medicine suppository is increased from 62 % to 72 % through the improvement of the preparation technology.
34. 103314109 用于抑制Hif1α表达的siRNA和含有其的抗癌组合物
CN
18.09.2013
C12N 15/113 Loading...
C12N 15/113
Loading...
201180063817.8
株式会社三养生物制药
金善玉
C12N 15/113
Loading...
本发明公开了一种小干扰RNA（siRNA），其互补地结合至Hif1αmRNA转录本的碱基序列，从而在不诱导免疫应答的情况下抑制Hif1α的表达，还公开一种siRNA在预防和/或治疗癌症中的应用。由于Hif1α通常在几乎所有的癌细胞中过表达，因此互补地结合至编码Hif1α的mRNA的siRNA可通过RNA介导的干扰（RNAi）来抑制Hif1α的表达，从而抑制癌细胞的增殖和转移，因此，siRNA可作为抗癌剂。
35. 103313705 含有利凡斯的明的经皮吸收制剂
CN
18.09.2013
A61K 9/70 Loading...
A61K 9/70
Loading...
201180062504.0
株式会社三养生物制药
柳贤硕
A61K 9/70
Loading...
公开了一种用于治疗痴呆的经皮吸收制剂，所述经皮吸收制剂包含利凡斯的明或其药学上可接受的盐作为活性成分、苯乙烯-异戊二烯-苯乙烯嵌段共聚物、增粘树脂和增塑剂，该制剂包含少量的利凡斯的明，但允许足够量的活性成分渗透到皮肤中来实现有效治疗痴呆。
36. 103269689 含有生理活性肽的微粒及其制备方法和包括该微粒的药物组合物
CN
28.08.2013
A61K 9/16 Loading...
A61K 9/16
Loading...
201180062181.5
株式会社三养生物制药
尹惠靖
A61K 9/16
Loading...
本发明公开了一种含有生理活性肽的微粒，制备该微粒的方法和包括该微粒的药物组合物。
37. 103269690 含有水难溶性药物的缓释聚合物微粒及其制备方法
CN
28.08.2013
A61K 9/16 Loading...
A61K 9/16
Loading...
201180062207.6
株式会社三养生物制药
李思元
A61K 9/16
Loading...
本发明公开了含有水难溶性药物的缓释聚合物微粒及其制备方法。
38. 103113464 天然人促红细胞生成素类似物
CN
22.05.2013
C07K 14/505 Loading...
C07K 14/505
Loading...
201310016616.3
沈阳三生制药有限责任公司
娄竞
C07K 14/505
Loading...
本发明涉及一种具有至少一个额外糖基化位点的促红细胞生成素类似物或其变体。本发明还涉及编码该促红细胞生成素类似物或其变体的DNA序列，以及供该类似物或其变体表达的重组质粒和宿主细胞。
39. 103073631 一种促红细胞生成素类似物
CN
01.05.2013
C07K 14/505 Loading...
C07K 14/505
Loading...
201310015836.4
沈阳三生制药有限责任公司
娄竞
C07K 14/505
Loading...
本发明涉及一种具有至少一个额外糖基化位点的促红细胞生成素类似物或其变体。本发明还涉及编码该促红细胞生成素类似物或其变体的DNA序列，以及供该类似物或其变体表达的重组质粒和宿主细胞。
40. 102970985 包含坦洛新或其药学可接受的盐的控释药物组合物及包含所述药物组合物的口服制剂
CN
13.03.2013
A61K 9/52 Loading...
A61K 9/52
Loading...
201180031846.6
株式会社三养生物制药
郑祜赈
A61K 9/52
Loading...
本发明提供了一种控释药物组合物及包含所述药物组合物的口服制剂，所述药物组合物包含第一组微粒和第二组微粒，所述微粒各自包含含有坦洛新或其药学可接受的盐的芯、在所述芯上形成的控释聚合物包衣层和在所述控释聚合物包衣层上形成的肠溶性聚合物外层，其中所述第一组微粒和所述第二组微粒中的各组的控释聚合物包衣层的平均厚度不同。该药物组合物可根据肠道中的pH变化和活性成分在小肠中的释放模式容易地控制所述活性成分的释放程度，由此避免所述活性成分快速转移到血液中，从而将副作用降至最低，并维持所述活性成分的有效血液浓度持续预定的时间。此外，即使在暴露在口内时，该组合物也可掩蔽所述活性成分的苦味，由此提高口服给药时对患者的疗效。
41. 202724266 一种振动选丸器
CN
13.02.2013
A61J 3/06 Loading...
A61J 3/06
Loading...
201220423662.6
三门峡广宇生物制药有限公司
张乐营
A61J 3/06
Loading...
一种振动选丸器，在底座上由上至下依次设置有与振动电机传动连接的撒粉盘、选丸筛、接丸盘、接粉盘，选丸筛的筛孔直径大于接丸盘的筛孔直径，选丸筛和接丸盘倾斜设置；选丸筛和接丸盘设有10度倾斜角；振动电机的振动输出端连接撒粉盘、选丸筛、接丸盘、接粉盘。本实用新型结构简单、功能实用，使大丸、异形丸、连体丸等不合格药丸在烘干前就收集重新利用，使制丸一次成型合格率由以前的85%提高到98%，药丸圆整度明显改善，减少了能耗，节省拣丸人工，提高了劳动生产率。
42. 202725055 一种中药混合器
CN
13.02.2013
B01F 3/14 Loading...
B01F 3/14
Loading...
201220423990.6
三门峡广宇生物制药有限公司
张乐营
B01F 3/14
Loading...
一种中药混合器，包括混合机，混合机的上口设有药膏缸，药膏缸的底部设有药膏给进装置，药膏给进装置底部设有下膏孔，药膏缸的底部且与药膏给进装置之间设有可水平方向移动调节的孔板，孔板上的孔与药膏给进装置的下膏孔对应设置；药膏给进装置底部均匀设有下膏孔；孔板的侧面连接设有药膏控制栓。本实用新型结构简单、功能实用，药膏持续均匀给进，与混合均匀的药粉均匀混合，使中药药粉与药膏混合时间大大缩短，且均匀度好，产品质量均质性明显改善，确保了产品质量。
43. 202725100 一种液体混合器
CN
13.02.2013
B01F 13/02 Loading...
B01F 13/02
Loading...
201220422090.X
三门峡广宇生物制药有限公司
张乐营
B01F 13/02
Loading...
一种液体混合器，包括混合罐，混合罐的顶部通过管道设有液体进口，混合罐的底部设有出口管，出口管的下端分支同时与压缩空气进口管道和混合液体出口管道相连通，压缩空气进口管道和混合液体出口管道上分别设有压缩空气进口阀门和混合液体出口阀门；液体进口的管道上设有液体进口阀门。本实用新型结构简单、功能实用，所配混合液体均匀度颇佳，产品质量明显改善。
44. 202724744 一种渗漉罐
CN
13.02.2013
B01D 11/02 Loading...
B01D 11/02
Loading...
201220423210.8
三门峡广宇生物制药有限公司
张乐营
B01D 11/02
Loading...
一种渗漉罐，包括罐体，罐体上部通过管道设有渗滤溶剂入口，在渗滤溶剂入口与罐体之间的管道上加装流量计，罐体底部一侧设有渗滤液出口，罐体底部另一侧设有取样口；渗滤液出口和取样口处分别设有渗滤液出口阀门和取样口阀门；渗滤溶剂入口的管道上设有渗滤溶剂入口阀门。本实用新型结构简单、功能实用，确保了渗滤溶剂的压力差，避免了人工操作的失误与差错，提高了产品质量。
45. 102740834 Polymer nanoparticle injection formulation composition containing rapamycin with improved water solubility, preparation method thereof, and anticancer composition for combined use with radiotherapy
CN
17.10.2012
A61K 9/127 Loading...
A61K 9/127
Loading...
201080060367.2
株式会社三养生物制药
姜惠媛
A61K 9/127
Loading...
The present invention relates to a polymer nanoparticle injection formulation composition containing rapamycin with improved water solubility, and more specifically, to an injection formulation composition containing rapamycin wherein water solubility is improved by solubilizing rapamycin having low water solubility with polymer nanoparticles, a preparation method thereof, and an anticancer composition for a combined use with radiotherapy.
46. 202315355 二效浓缩器
CN
11.07.2012
B01D 1/26 Loading...
B01D 1/26
Loading...
201120450623.0
三门峡广宇生物制药有限公司
王广宇
B01D 1/26
Loading...
二效浓缩器，包括一效加热器、一效蒸发器、二效加热器和二效蒸发器，一效加热器与一效蒸发器通过管路连接，二效加热器与二效蒸发器通过管路连接，一效蒸发器的上侧出口与二效加热器连通，一效加热器的下方设有蒸汽入口，一效蒸发器和二效蒸发器底部均设有药液入口，所述二效蒸发器的上方出口通过管路依次与冷凝器、乙醇储罐连接，乙醇储罐的上侧出口与真空缓冲罐连接。本实用新型与现有技术中的双效浓缩器相比，本实用新型在原系统中增设一组板式冷凝器和一个乙醇储罐，该板式冷凝器连接二效蒸发器与乙醇储罐，乙醇储罐连接真空缓冲罐，加大了药液醇蒸气的冷却效果，乙醇回收快，回收率高。乙醇回收速度由原来的750kg/天提高到1500kg/天，乙醇收率由原来的40%提高到98%。
47. 202315399 一种乙醇提取罐
CN
11.07.2012
B01D 11/02 Loading...
B01D 11/02
Loading...
201120451515.5
三门峡广宇生物制药有限公司
王广宇
B01D 11/02
Loading...
本实用新型公开了一种乙醇提取罐，包括罐体，罐体底部设有药液排出管，药液排出管上设有第一开关阀，还包括冷凝器，药液排出管上在第一开关阀与罐体之间设有热空气进管，热空气进管上设有第二开关阀，罐体顶部设有乙醇蒸汽出管，乙醇蒸汽出管与冷凝器的进气口连接，冷凝器上设有乙醇液体出口和空气出口。本实用新型设计合理、结构简单，使用方便快捷，在现有的提取罐上加设热空气进管及第二阀门即可达到提取回收药渣中残留的乙醇，从而实现节约成本的目的。
48. 102458373 生物利用度提高的包含难溶性药物的微球及其制备方法
CN
16.05.2012
A61K 9/16 Loading...
A61K 9/16
Loading...
201080029072.9
株式会社三养生物制药
金京熙
A61K 9/16
Loading...
本文提供了生物利用度提高的包含难溶性药物的微球、包含所述微球的口服制剂以及制备所述微球的方法。所述包含难溶性药物的微球是通过喷雾干燥方法使难溶性药物以非晶体形式分散于水溶性高分子载体中的固体分散体，因此具有提高了难溶性药物的生物利用度的优点。
49. 102349996 人乳头瘤病毒药物组合物及其应用
CN
15.02.2012
A61K 39/12 Loading...
A61K 39/12
Loading...
201110313514.9
沈阳三生制药有限责任公司
娄竞
A61K 39/12
Loading...
本发明涉及一种用于预防和治疗由人乳头瘤病毒所引起相关疾病的人乳头瘤病毒药物组合物，其特征在于由以下成分组成：为活性成分的人乳头瘤病毒样颗粒(HPV VLPs)、为促进免疫反应的佐剂，为激活细胞免疫使之持久且高效产生免疫应答的细胞因子免疫促进剂、为维持VLPs完整空间构型和一定溶解度的盐溶液、维持一定pH值生理上可相溶的缓冲液、保护VLPs避免剧烈震荡而导致活性下降的非离子表面活性剂、余量为水。其特点是将HPV VLPs制备成保持其完整的空间构型的、高效免疫的、储存稳定的液体药物组合物。用于预防和治疗由于HPV感染所导致的各类疾病，具有使用安全、方便、经济、无任何副作用等特点。
50. 102300556 Pharmaceutical composition containing an anionic drug, and a production method therefor
CN
28.12.2011
A61K 9/127 Loading...
A61K 9/127
Loading...
200980156062.9
株式会社三养生物制药
金世浩
A61K 9/127
Loading...
Disclosed is a pharmaceutical composition containing an anionic drug, characterised in that it comprises: an anionic drug as an active component; a cationic lipid; and an amphiphilic block copolymer, and in that the anionic drug forms a complex with the cationic lipid, and the complex is enclosed within a micelle structure of the amphiphilic block copolymer. Also disclosed is a production method for this pharmaceutical composition. The pharmaceutical composition is advantageous in that it can improve the efficacy of anionic drugs since it allows delivery into cells and it can increase the stability of anionic drugs in the blood or in body fluids.
51. 102271662 Pharmaceutical composition of lyophilized formulation and preparation method of the same
CN
07.12.2011
A61K 9/19 Loading...
A61K 9/19
Loading...
200980153201.2
株式会社三养生物制药
徐敏孝
A61K 9/19
Loading...
Disclosed is a pharmaceutical composition of a lyophilized formulation including a multiblock copolymer in which two or more ABA-type triblocks are covalently connected through biodegradable dicarboxylic linkage, wherein A represents a polyethylene oxide block and B represents a polypropylene oxide block, a polybutylene oxide block, or a block of copolymer of propylene oxide and butylene oxide, the multiblock copolymer being included in an amount of 1 to 7 wt% based on the total weight of solution prior to the lyophilized formulation. The composition is capable of reducing reconstitution time of a lyophilized sustained-release formulation.
52. 102264351 包含水溶性差的药物的聚合胶束组合物的制备方法
CN
30.11.2011
A61K 9/127 Loading...
A61K 9/127
Loading...
200980152890.5
株式会社三养生物制药
徐敏孝
A61K 9/127
Loading...
本发明提供了制备包含药物的聚合胶束组合物的方法，其包括：将药物和两亲嵌段共聚物溶于有机溶剂中；以及将水溶液加入到在所述有机溶剂中所得的混合物中以形成聚合胶束，其中所述方法不需要在胶束形成之前移除所述有机溶剂的单独操作。所述制备包含药物的聚合胶束组合物的方法简单、缩短了处理时间、并且适于大规模生产。
53. 102209743 Highly purified polylactic acid or a derivative thereof, a salt of the same, and purification method thereof
CN
05.10.2011
C08G 63/08 Loading...
C08G 63/08
Loading...
200980144492.9
株式会社三养生物制药
金峯吴
C08G 63/08
Loading...
Disclosed are a highly purified polylactic acid or a derivative thereof, or a salt thereof, and a method for purifying the same. The polylactic acid or a derivative thereof, or a salt thereof may be applied to various medical and drug carrier systems, or the like.
54. 101910246 Highly pure amphiphilic copolymer comprising hydrophobic block from alpha-hydroxy acid and process for the preparation thereof
CN
08.12.2010
C08G 63/91 Loading...
C08G 63/91
Loading...
200880123623.0
Samyang Corporation
Kim Bong Oh
C08G 63/91
Loading...
Disclosed are a highly pure amphiphilic block copolymer including a hydrophobic polymer block of a po Iy ( a -hydroxy acid), and a method for preparing the same. The method for preparing a highly pure amphiphilic block copolymer including a hydrophobic polymer block of a po Iy ( a -hydroxy acid) includes removing a -hydroxy acid, lactone monomers thereof, oligomers thereof and an organometal catalyst in polymerizing the amphiphilic block copolymer.
55. 101910274 Amphiphilic block copolymer micelle composition containing taxane and manufacturing process of the same
CN
08.12.2010
C08K 5/04 Loading...
C08K 5/04
Loading...
200880123622.6
株式会社三养生物制药
李思元
C08K 5/04
Loading...
A taxane-containing amphiphilic block copolymer micelle composition, including taxane, an amphiphilic block copolymer containing a hydrophilic block and a hydrophobic block, and an osmolality adjusting agent, is discribed. Also described are a method for preparing the same composition. The composition has excellent stability so that it can prevent rapid release of a drug and can improve a desired pharmacological effect. Additionally, the method enables highly efficient preparation of the composition.
56. 101809446 Sol-gel phase-reversible hydrogel templates and uses thereof
CN
18.08.2010
C08J 3/075 Loading...
C08J 3/075
Loading...
200880109047.4
株式会社三养生物制药
基纳姆·帕克
C08J 3/075
Loading...
Discrete microstructures of predefined size and shape are prepared using sol-gel phase- reversible hydrogel templates. An aqueous solution of hydrogel-forming material is covered onto a micro fabricated silicon wafer master template having predefined microfeatures, such as pillars. A hydrogel template is formed, usually by lowering the temperature, and the formed hydrogel template is peeled away from the silicon master template. The wells of predefined size and shape on the hydrogel template are filled with a solution or a paste of a water-insoluble polymer, and the solvent is removed to form solid structures. The formed microstructures are released from the hydrogel template by simply melting the hydrogel template in water. The microstructures are collected by centrifugation. The microstructures fabricated by this method exhibit pre-defined size and shape that exactly correspond to the microwells of the hydrogel template. The method of preparing microstructures based on hydrogel templates is simple and can easily produce large quantities of the microstructures.
57. 101337988 New erythrocyte-stimulating factor analogues
CN
07.01.2009
C07K 14/505 Loading...
C07K 14/505
Loading...
200710127362.7
Shenyang Sunshine Pharmaceutical Co., Ltd.
Lou Jing
C07K 14/505
Loading...
The invention relates to an erythropoietin analog with at least one extra glycosylation sites or a variant thereof. The invention also relates to a DNA sequence for coding the erythropoietin analog or the variant thereof, and a recombinant plasmid and a host cell for expressing the analog or the variant thereof.
58. 101045923 Process of producing interleukin analog
CN
03.10.2007
C12N 15/09 Loading...
C12N 15/09
Loading...
200610046222.2
Shenyang Sansheng Pharmaceutical Co., Ltd.
Su Dongmei
C12N 15/09
Loading...
The colibacillus expression and hydrophobic chromatographic purification to produce protein with amino acid sequence similar to that of human interleukin-2 can obtain protein with specific activity after being purified not lower than 1x108 IU/mg.
59. 1964744 Delivery system for bioactive agents on the basis of a polymeric drug carrier comprising an amphiphilic block polymer and a polylacticacid derivative
CN
16.05.2007
A61K 47/34 Loading...
A61K 47/34
Loading...
200580018124.1
株式会社三养生物制药
李一雄
A61K 47/34
Loading...
Delivery system for bioactive agents on the basis of a polymeric drug carrier formed from compositions comprising an amphiphilic block copolymer of a hydrophilic block and a hydrophobic block having a terminal hydroxyl group substituted with a tocopherol or cholesterol group, and a polylactic acide derivative wherein one end of the polylactic acid is covalently bound to at least one carboxyl group. The carboxyl group of the polylactic acid derivative may be fixed with a di- or trivalent metal ion,which is obtained by adding the di- or trivalent metal ion to the polymeric composition.
60. 1895281 Chinese-medicinal preparation and making method for treating acute corneitis and releasing visual fatigue
CN
17.01.2007
A61K 35/413 Loading...
A61K 35/413
Loading...
200610016968.9
Sanjiu Biological Pharmaceutical Co., Ltd., Changchun
Huang Linqing
A61K 35/413
Loading...
A Chinese medicine for treating acute conjunctivitis and keratitis and relaxing visual fatigue is prepared from bear gall and borneol. Its preparing process is also disclosed.
61. 1876811 Preparation method of recombinant human alpha interferon
CN
13.12.2006
C12N 15/09 Loading...
C12N 15/09
Loading...
200510046590.2
Shenyang Sunshine Pharmaceutical Co., Ltd.
Lu Jun
C12N 15/09
Loading...
The invention discloses a method for preparation of interferon. The method includes extracting inclusion body after the fermentation of bacillus coli having coding interferon alpha ribonucleotide sequence, applying affinity tomographic column to perform reclamation and purification for the inclusion body, then performing ion-exchange chromatography, anti-phase high performance liquid chromatography and gel exclusion chromatography to obtain high-purity recombination alpha interferon.
62. 1842339 Internally administered therapeutic agents for cranial nerve diseases comprising mesenchymal cells as an active ingredient
CN
04.10.2006
A61K 35/28 Loading...
A61K 35/28
Loading...
200480024645.3
Renomedix Inst Inc.
Honmou Osamu
A61K 35/28
Loading...
Intravenous administration of bone marrow cells collected from rat bone marrow to a rat cerebral infarction model was found to be effective in treating cerebral infarction. Human and murine bone marrow stem cells showed similar effects. Mesenchymal cells such as bone marrow cells, cord blood cells, or peripheral blood cells can be used as agents for in vivo administration against cranial nerve diseases.
63. 1634107 Small injectio of hawthorn leaf total flavone and its preparation process
CN
06.07.2005
A61K 9/08 Loading...
A61K 9/08
Loading...
200410085457.3
Changchun Sanjiu Bio-Pharmaceutical Co., Ltd.
Huang Linqing
A61K 9/08
Loading...
The invention discloses a small injection of hawthorn leaf total flavone and its preparation process, by adjusting pH, the problem of low dissolution performance of the haw thorn leaf flavones is solved, by controlling pH range and employing anti-oxidant, the problem of poor stability of the haw thorn leaf flavones is solved, the obtained preparation has better stability, high biological availability, and precise curative effect. The powder injection can be used for the treatment for cranial vascular diseases.
64. 1519021 Stable erythropoietin of recombined human red blood cell
CN
11.08.2004
A61K 38/18 Loading...
A61K 38/18
Loading...
03100653.1
Sansheng Pharmacy Co., Ltd., Shenyang
Hou Xufeng
A61K 38/18
Loading...
A stable recombinant human guanophore poietin (rHuEPO) in the form of injection for treating renal anemia and the anemia caused by surgical operation and chemicotherapy contains rHuEPO, mannitol as protein protector, sodium chloride as the isotonic agent of buffer liquid and water. Its advantages are high safety and no by-effect.
65. 1518459 Remedies for eosinophilic diseases
CN
04.08.2004
A61K 38/17 Loading...
A61K 38/17
Loading...
02812505.3
Daiichi Suntory Pharmaceutical Ltd.
Mirua Kenju
A61K 38/17
Loading...
Remedies for eosinophilic diseases containing as the active ingredient a substance which induces apoptosis of eosinophils via CD30 and/or a molecule participating in the signal transfer of CD30. These remedies are efficacious against allergic diseases, respiratory diseases, skin diseases, autoimmune diseases, immunodeficient diseases, digestive diseases, tumor diseases and parasitogenic diseases.
66. 1505603 Substituted benzoic ac id derivatives exhibiting nf-kappab inhibiting activity
CN
16.06.2004
C07C 66/00 Loading...
C07C 66/00
Loading...
02802873.2
Suntory Ltd
Nunokawa Yoichi
C07C 66/00
Loading...
A substituted benzoic acid derivative which is represented by the following formula (I) and has an NF-kappaB inhibiting action (in the formula, R3, R4 and R5 each independently represents a hydrogen atom, an alkyl group having 1 to 6 carbon(s) or an alkoxy group having 1 to 6 carbon(s); R9 and R10 each independently represents a hydrogen atom, an alkyl group having 1 to 6 carbon(s) or an acyl group having 2 to 11 carbons); R2 represents an optionally-substituted aromatic hydrocarbon group or an optionally-substituted heterocyclic group; and X represents a carboxyl group which may be esterified or amidated).
67. 1466993 Recombination alpha-interferon gelatin injection
CN
14.01.2004
A61P 15/02 Loading...
A61P 15/02
Loading...
02132574.X
Shenyang Sunshine Pharmaceutical Co., Ltd.
Zhao Huilin
A61P 15/02
Loading...
A recombinant human alpha-interferon gel in the injection for treating the viral vagina diseases of woman contains the recombinant human alpha-interferon as active component, the carbomer as the gel matrix, the antiseptic compatible with interferon, the sodium hydroxide or triethanolamine as neutralizer of carbomer, and water. Its advantages are no irritation and pollution to clothes, and no any by-effect.
68. 1466466 Remedies for heart failure
CN
07.01.2004
A61K 31/7076 Loading...
A61K 31/7076
Loading...
01816531.1
Suntory Limited
Kawashima Kayoko
A61K 31/7076
Loading...
The present invention provides methods for screening drugs inhibiting the expression of OSF-2 gene or the production or function of the protein encoded thereby and therapeutic agents for heart failure having such effects. Useful methods for diagnosing heart failure can be provided by monitoring the expression or variation of said gene or the production of the protein encoded thereby. The present invention also provides transgenic animals with forced expression of OSF-2 gene and methods for studying changes in gene expression or protein production or the functions of various genes or proteins with the progress of the pathology of heart failure using them and novel therapeutic agents for heart failure.
69. 1460097 NF-kB inhibitor containing substituted benzoic acid derivative as active ingredient
CN
03.12.2003
C07C 65/40 Loading...
C07C 65/40
Loading...
02800894.4
Daiichi Suntory Seiyaku Co., Ltd.
Suzuki Kenji
C07C 65/40
Loading...
A novel NF- kappa B inhibitor represented by the following formula (I) is provided.
70. 1338463 Method for improving stability of polypeptide in body and its application
CN
06.03.2002
C07K 14/00 Loading...
C07K 14/00
Loading...
01128011.5
Sansheng Pharmaceutical Co Ltd, Shenyang
Luo Jing
C07K 14/00
Loading...
A method for improving the stability of polypetide in body features that on the basis of organic chemistry, the polypeptide is linked to human serum albumin at inside or outside of body, including using special chemical molecular to modify the polypeptide composed of 5-100 amino acids at outside of body.
71. 1278177 Neovascularization promoters
CN
27.12.2000
A61P 9/00 Loading...
A61P 9/00
Loading...
98810630.2
yoshitomi Pharmaceutical Industries, Ltd.
Mizushima Yutaka
A61P 9/00
Loading...
Neovascularization promoters which contain as the active ingredient compounds represented by general formula (I), wherein R<1> represents acyl; R<2> represents alkyl; R<3> and R<4> are the same or different and each represents hydrogen or a hydroxy-protective group; and R<5> represents alkyl. These compounds not only have the effect of promoting neovascularization by themselves but also potentiate neovascularization by drugs having neovascularizing effects such as b-FGF. Therefore, there compounds can potentiate the neovascularization in an ischemic tissue or at a site where b-FGF is locally increased due to other pathological factors.
72. 1276165 Formulation and process for producing calcium-enriched chocolate
CN
13.12.2000
A23L 1/304 Loading...
A23L 1/304
Loading...
00109613.3
Sansheng Pharmaceutical Co., Ltd., Shenyang
Jiang Yan
A23L 1/304
Loading...
A calcium-enriched chocolate is prepared from alkali extracted cocoa, oligofractose, emulsifier, calcium and VD3 through mixing, fine grinding, refining, mixing,regulating temp, shaping, cooling and packing. Its advantages are natural fruit smell and health-care function of making bone and teeth stronger and preventing osteoporosis.
73. 1276382 Process for preparing recombined human thrombopoietin preparation
CN
13.12.2000
A61K 38/27 Loading...
A61K 38/27
Loading...
00109612.5
Sansheng Pharmaceutical Co., Ltd., Shenyang
Lu Mingjian
A61K 38/27
Loading...
A process for large-scale preparing recombined human thrombopoietin includes such steps as culturing the transformed mammal cells carrying coded human thrombopoietin protein gene sequence in special culture medium under special condition to obtain high-expression liquid of said protein product, ion exchange chromatography, inverse high efficiency liquid-phase chromatography and gel filtering purification. The product has high purity and bioactivity.
74. 1255377 Stable recombinational human interferon preparation
CN
07.06.2000
A61K 38/21 Loading...
A61K 38/21
Loading...
99113391.9
Sansheng Pharmaceutical Co., Ltd., Shenyang
Zou Zhongcheng
A61K 38/21
Loading...
The present invention discloses a process for preparing the gene recombined protein (recombinational human alpha-interferon IFN) preparation, which does not contain human albumen, is ableto be muturally dissolved and has high stability for storage. Said preparation contains gene engineering recombination protein (IFN-alpha), a physiologically mutually-dissolved buffer liquid, and optional iso-osmotic regulator, complexing agent, protecting agent and others for injection. Its preparing process includes preparing buffer liquid of citrate, adding said optional components, introducing aseptically filtered nitrogen to make the oxygen content in solution less than 0.25 ppm, and adding IFN-alpha protein to obtain injection.
75. 1190130 Preparation of recombined erythropoietin preparation
CN
12.08.1998
C12N 15/67 Loading...
C12N 15/67
Loading...
98100248.X
Shenyang Sansheng Pharmaceutical Co., Ltd.
Lou Dan
C12N 15/67
Loading...
The method for mass producing human erythropoietin includes the culture of converted mammal cell carrying erythropoietin DNA code sequence in culture medium with insulin and transferrins and under specific condition to obtian the high expression of the said protein product. The obtained liquid rich in erythropoietin is processed through the successive affinity chromatography, ion exchange, reversed phase high-performance liquid filtration and gel filtration to purify so as to obtain human erythropoietin with high purity and high biological activity.
76. 1127785 Human thrombopoietin
CN
31.07.1996
C07K 14/435 Loading...
C07K 14/435
Loading...
95110172.2
Li Weike
Li Weike
C07K 14/435
Loading...
A new structure of TPO, a growing factor of artificial blood, is disclosed. m RNA is extracted from fetus lung, and reverse transcribed to become cDNA library. After screening, cDNA of the TPO is obtained. Through PCR reaction, its cloned product is obtained, which is connected with each expression vector respecitvely for transforming colibacillus, mammal cell and insect cell, resulting in expression system for colibacillus, mammal cell and rhabdovirus.

